Search
Partnering in Oncology & Cancer Imm HP OCTOBER 2024 CORP.pdf
KISIMA® cancer vaccine
Research Collaborations
Research Collaborations
Clinical Collaborations
Clinical Collaborations
Vargatef®
Combination therapy with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
Sales consultant about working with purpose
Bok talks about how he found purpose in his career. After his father was diagnosed with cancer, he decided to work as an oncology sales consultant.
Introduction to head-to-head trials
Hear from experts Dr Kerr and Dr Melosky.
Giotrif®
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous hist
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Science Focus
Science Focus
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
SIRPα antagonist
SIRPα antagonist
Oncology
Human Pharma Clinical Pipeline Oncology therapeutic area
Boehringer Ingelheim Advances Oncology Research
Boehringer Ingelheim Advances Its Oncology Research Program Through Innovative Partnerships
Ezabenlimab, PD-1 antibody
Ezabenlimab, PD-1 antibody
VSV-GP
VSV-GP
Congress Patient Benefit
The participation in scientific congresses is firmly established in the event agenda of any pharmaceutical company. But what is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical represent
CD137/FAP agonist
CD137/FAP agonist
Lung Diseases
Lung Diseases
Women in STEM: Passion for science
Discover how our women excelling in STEM careers can improve health equity and create sustainable healthcare solutions.
Option to Acquire Trutino Biosciences
Option to Acquire Trutino Biosciences
BI 764532: DLL3/CD3 T-cell engager
BI 764532: DLL3/CD3 T-cell engager
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
Obesity
Obesity